Yasuhiko Matsumori

Characterizing the clinical profile of primary headache using explainable artificial intelligence.

Journal: Cephalalgia : an international journal of headache

Published: August 25, 2026

Comparative diagnostic agreement of a supervised machine learning model and a general-purpose, zero-shot, non-domain-adapted large language model for classifying headache disorders using structured questionnaires.

Journal: Cephalalgia : an international journal of headache

Published: August 24, 2026

Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study.

Journal: Journal of clinical medicine

Published: July 21, 2026

Spontaneous intracranial hypotension with negative brain MRI findings: a systematic review of diagnostic strategies and clinical outcomes.

Journal: Frontiers in neurology

Published: April 16, 2026

Cenobamate use in super-refractory status epilepticus: A report of three cases.

Journal: Epileptic disorders : international epilepsy journal with videotape

Published: February 19, 2026

Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.

Journal: BMC public health

Published: January 03, 2026

Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study.

Journal: Advances in therapy

Published: December 29, 2025

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.

Journal: Neurology and therapy

Published: December 23, 2025

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Journal: The journal of headache and pain

Published: December 17, 2025

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants.

Journal: The patient

Published: December 14, 2025

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis.

Journal: The journal of headache and pain

Published: December 14, 2025

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.

Journal: Cephalalgia : an international journal of headache

Published: October 15, 2025

Characterizing the clinical profile of primary headache using explainable artificial intelligence.

Characterizing the clinical profile of primary headache using explainable artificial intelligence.

Comparative diagnostic agreement of a supervised machine learning model and a general-purpose, zero-shot, non-domain-adapted large language model for classifying headache disorders using structured questionnaires.

Comparative diagnostic agreement of a supervised machine learning model and a general-purpose, zero-shot, non-domain-adapted large language model for classifying headache disorders using structured questionnaires.

Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study.

Adjunctive Fasudil Use and Outcomes After Clazosentan Treatment for Aneurysmal Subarachnoid Hemorrhage: A Multicenter DCI Japan Registry Study.

Spontaneous intracranial hypotension with negative brain MRI findings: a systematic review of diagnostic strategies and clinical outcomes.

Spontaneous intracranial hypotension with negative brain MRI findings: a systematic review of diagnostic strategies and clinical outcomes.

Cenobamate use in super-refractory status epilepticus: A report of three cases.

Cenobamate use in super-refractory status epilepticus: A report of three cases.

​​Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.

​​Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.

Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study.

Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study.

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.

Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study.

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study.

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants.

Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants.

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis.

Effectiveness and safety of anti-CGRP monoclonal antibodies in hemiplegic migraine: an individual patient quantitative analysis.

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.

Efficacy and safety of eptinezumab in a predominantly Asian population with chronic migraine: Results of the randomized, double-blind, placebo-controlled SUNRISE trial.

Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.

Trends in self-reported headache disorder in Spain between 2006 and 2023: the role of sociodemographic factors.